FDA
-
-
-
-
-
-
-
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Eisai and Nuvation Bio secure European drug application validation
-
-
-
-
-
-
-
Nuvation Bio reports $24.7 million in revenue for cancer drug IBTROZI
-
-
-
-
-
-
-
B.Riley Starts Nuvation Bio Inc (NUVB) at Buy
-
-
-
-
-
-
-
Nuvation Bio gets Japan approval for lung cancer drug IBTROZI
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
-
-
-
-
-
-
-
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
-
323,584 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

